Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus

Several efforts have been made to improve the available therapeutic armamentarium of patients with immunemediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.

Automated summary

Biobetters are a new type of treatment for patients with IMIDs, which require clinical studies to validate their definition. An appropriate balance between clinical outcomes and costs, as well as a shared decision between physicians and patients, should guide the use of biobetters.